Last reviewed · How we verify
(-)-Irofulven (IROFULVEN)
Irofulven works by inhibiting the serine/threonine-protein kinase Chk2, a protein involved in DNA repair and cell cycle regulation.
-)-Irofulven (IROFULVEN) is a small molecule modality targeting the serine/threonine-protein kinase Chk2. Its development is attributed to an unspecified original developer, and its current ownership is unknown. Irofulven's commercial status and approved indications are unclear. The compound has a short half-life of 0.3 hours, but its bioavailability and off-patent status are unknown. Further research is needed to determine its potential as a therapeutic agent.
At a glance
| Generic name | IROFULVEN |
|---|---|
| Target | Serine/threonine-protein kinase Chk2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Think of Chk2 like a quality control manager in a factory. When DNA damage is detected, Chk2 helps to stop the cell from dividing until the damage is fixed. Irofulven blocks Chk2's ability to do this, which can lead to cell death in cancer cells.
Approved indications
Common side effects
Key clinical trials
- Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) (PHASE2)
- Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors (PHASE1,PHASE2)
- Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer (PHASE2)
- Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer (PHASE2)
- Irofulven in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
- Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer (PHASE2)
- Study of Irofulven in Patients With Hormone-refractory Prostate Cancer (PHASE2)
- Irofulven in Treating Patients With Metastatic or Recurrent Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- (-)-Irofulven CI brief — competitive landscape report
- (-)-Irofulven updates RSS · CI watch RSS